RIDE-001 was developed using Trained Therapeutix’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This ...
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but ...
News Medical on MSN
Targeting myeloid cells to enhance cancer immunotherapy
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two ...
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...
About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...
Infusions of PF4 have reversed aging in human hematopoietic stem cells. Could this lead to future treatments for aging ...
The Brighterside of News on MSN
New nanodrug is 20,000x more lethal to leukemia while sparing healthy cells
Cancer treatment has always been a balancing act—hit the tumor hard enough to kill it, but not so hard that the patient ...
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback